Venous Thromboembolic Risk Does Not Increase After a Third Dose of SARS-CoV-2 mRNA-BNT162b2 Vaccine in Cancer Patients Receiving Active Systemic Therapies: Updated Results from the Vax-On-Third-Profile Study
Vaccines,
Journal Year:
2025,
Volume and Issue:
13(4), P. 392 - 392
Published: April 8, 2025
(1)
Background:
Clinical
evidence
has
raised
concerns
regarding
a
potential
link
between
COVID-19
mRNA-based
vaccines
and
the
occurrence
of
thromboembolic
events.
So
far,
no
research
explored
effects
this
possible
interaction
in
cancer
patients
undergoing
active
treatment.
We
leveraged
prospective
monitoring
from
Vax-On-Third-Profile
study
to
examine
development
venous
thromboembolism
(VTE)
after
third
dose
mRNA-BNT162b2
(tozinameran)
its
association
with
antibody
lymphocyte
responses.
(2)
Methods:
Patients
who
had
received
tozinameran
not
experienced
any
VTE
previous
30
days
were
eligible.
A
serological
evaluation
was
conducted
before
booster
vaccination
(timepoint-1)
four
weeks
thereafter
(timepoint-2)
measure
titers
against
SARS-CoV-2
spike
protein,
as
well
determine
absolute
counts
T-helper
cells,
T-cytotoxic
B
NK
cells.
Data
acquired
November
2021
October
2022
analyzed
2023.
(3)
Results:
The
present
involved
429
given
26
September
2021.
Among
treatments
interest,
109
(25.4%)
targeted
therapy,
111
(25.9%)
cytotoxic
chemotherapy,
39
(9.1%)
immune
checkpoint
inhibitors,
21
(4.9%)
endocrine
(7.0%)
combination
chemotherapy
agents
eight
preceding
dosing.
In
addition,
119
(27.7%)
discontinued
systemic
therapy
for
at
least
12
accounted
reference
subgroup.
After
median
follow-up
time
10.6
(95%
CI
8.1-11.7)
months,
we
observed
31
events
general
population,
an
overall
incidence
rate
7.2%
5.0-10.1).
immunization
99
85-112)
days.
univariate
comparison,
exposed
therapies
(11.3%
[95%
6.0-18.9];
p
=
0.030)
or
inhibitors
(16.2%
6.2-32.0];
0.012)
significantly
higher
than
cohort
(3.4%
0.9-8.5]).
Univariate
analysis
responses
showed
that
only
dynamic
changes
pertaining
cell
distributions
correlated
occurrence.
Multivariate
regression
confirmed
high-level
response
(OR
6.10
[9%
2.16-17.21];
0.001),
history
9.81
[3.99-24.13];
<
presence
central
catheter
5.02
1.84-13.67];
0.002)
independently
associated
increased
risk
VTE.
(4)
Conclusions:
This
provides
unprecedented
have
developing
tozinameran,
regardless
type
therapy.
specific
pattern
appears
increase
risk,
underlying
dysregulation
causal
cofactor.
These
findings
emphasize
need
additional
periodic
patients.
Language: Английский
Serological response and immune‐related adverse events following COVID‐19 vaccination in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta‐analysis
Reviews in Medical Virology,
Journal Year:
2023,
Volume and Issue:
34(1)
Published: Nov. 28, 2023
Abstract
With
the
popularity
of
Coronavirus
disease
2019
(COVID‐19)
vaccine
and
development
vaccination
strategies,
impact
COVID‐19
on
cancer
patients
receiving
immune
checkpoint
inhibitors
(ICIs)
is
still
unclear.
In
systematic
review
meta‐analysis
with
ICIs,
we
assessed
serological
response
vaccine,
explored
risk
related
adverse
events
(irAEs).
We
searched
PubMed,
EMBASE
Cochrane
Library
as
10
June
2023,
included
who
received
ICIs
vaccine.
The
include
cohort
study,
cross‐sectional
study
case
report.
outcome
response,
Spike‐specific
T‐cell
irAEs
rare
events.
When
possible,
data
were
analysed
by
random
effect
analysis,
statistical
heterogeneity
was
Q‐test
I
2
statistics.
sources
through
L’Abbe
plots,
Galbraith
radial
sensitivity
analysis.
publication
bias
evaluated
Egger's,
Begg's
linear
regression
test
funnel
plot,
further
trim
fill
method.
27
studies
eligible
(19
studies,
1
7
reports),
involving
8331
(with
4724
ICIs).
Most
used
mRNA
(BNT162b2
or
mRNA‐1273).
Compared
chemotherapy,
significantly
more
likely
to
have
seroconversion
(RR
=
1.05,
95%CI
1.01–1.10,
P
0.02).
There
no
statistically
significant
differences
in
rates
when
comparing
controls
without
0.95,
95%
CI
0.89–1.01,
0.09)
targeted
therapy
0.79–1.39,
0.75).
incidence
before
after
(21.96%,
16.66%–28.94%)
(14.88%,
8.65%–25.57%),
respectively.
most
common
endocrine
abnormalities,
skin
disorders,
etc.
certainty
evidence
low
compared
those
very
versus
cancer.
Cancer
treated
seem
be
able
receive
safely
increasing
irAEs.
Language: Английский
Patients with advanced cancer were treated with immune checkpoint inhibitors and injected with COVID-19 vaccine to improve their prognosis without increasing pancreatic related adverse events
Min Li,
No information about this author
Lingling Liao,
No information about this author
Wei Huang
No information about this author
et al.
Human Vaccines & Immunotherapeutics,
Journal Year:
2024,
Volume and Issue:
20(1)
Published: June 5, 2024
To
investigate
immune
checkpoint
inhibitors
(ICIs)
induced
pancreatic
injury
(ICIPI),
the
prognostic
effect
of
COVID-19
vaccine
on
cancer
patients,
and
whether
increases
incidence
ICIPI.
We
conducted
a
retrospective
study
256
stage
IV
patients
treated
with
ICIs
at
The
First
Affiliated
Hospital
Anhui
Medical
University
from
January
2020
to
November
2022.
Data
collected
included
enzyme
levels,
treatment
outcomes,
vaccination
status.
Statistical
significance
was
determined
using
χ2
test
Kaplan-Meier
method
(p
<
.05).
Compared
control
group,
vaccinated
group
.0001)
elevated
levels
=
.044)
demonstrated
higher
disease
rates,
indicating
direct
benefit
monitoring
outcomes.
Additionally,
longer
overall
survival
versus
unvaccinated
(23.9
months
[95%
CI,
22.3–25.5]
vs
23.6
21.1–26.2],
HR
0.45
0.24–0.86],
p
.015)
progression-free
(17.2
14.3–20.1]
13.7
11.3–16.1],
0.54
0.36–0.82],
.004).
Importantly,
analysis
revealed
no
significant
association
between
.46).
Monitoring
enzymes
can
effectively
evaluate
therapeutic
impact
in
ICIs.
Patients
against
experience
better
immunotherapy
outcomes
without
an
increased
risk
Language: Английский
Antecedent viral immunization and efficacy of immune checkpoint blockade: an extensive serum antibody profile to predict outcomes in non-small cell lung cancer
Journal for ImmunoTherapy of Cancer,
Journal Year:
2024,
Volume and Issue:
12(11), P. e009931 - e009931
Published: Nov. 1, 2024
Immune
checkpoint
blockers
(ICBs)
revolutionized
the
treatment
of
patients
with
advanced
non-small
cell
lung
cancer
(NSCLC)
but
only
a
fraction
them
obtain
response,
and
clinical
benefit
from
these
treatments
is
often
difficult
to
predict.
The
aim
our
study
unveil
potential
implications
antibody
response
previous
viral
infections
in
predicting
ICBs
NSCLC.
Sera
treated
alone,
chemotherapy
(CT)
or
combination
CT-ICBs
were
analyzed
VirScan
(CDI
Labs,
USA),
high-throughput
method
that
comprehensively
analyzes
epitope-level
antiviral
IgG
antibodies
via
programmable
phage
display
immunoprecipitation
sequencing.Total
number
unique
positive
peptides
(tUP)
was
defined
as
total
non-overlapping
"is
hit"
for
each
patient.
Overall,
387
included.
Of
them,
129
66
195
CT
alone.
90
out
alone
received
subsequent
line
treatment,
while
administered
upfront
therapies.A
higher
tUP
correlated
improved
overall
survival
ICBs,
confirmed
multivariate
model
(HR
0.43,
95%
CI
0.24,
0.79,
p=0.006),
it
not
those
(p=0.8)
(p=0.1).tUP
programmed
death-ligand
1
(PD-L1)
expression,
at
transcriptome
level
several
immune-related
pathways,
particularly
involving
B
cells.
A
recognized
by
serum
might
reflect
increased
immune
fitness,
resulting
outcomes
Language: Английский